摘要
目的:探讨达格列净辅助治疗2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者的效果。方法:选取2020年6月-2021年10月哈尔滨市第一医院收治的96例T2DM合并MAFLD患者作为观察对象。根据随机数字表法将其分为对照组和观察组,各48例。两组均给予饮食指导。对照组给予常规降糖治疗,观察组在对照组基础上给予达格列净片。比较两组治疗前及治疗24周后血糖、胰岛功能、血脂、肝功能、肝脂肪含量与肝脾密度比。结果:治疗24周后,观察组糖化血红蛋白(HbA1c)、空腹血糖(FPG)、胰岛素抵抗指数(HOMA-IR)均低于对照组(P<0.05)。治疗24周后,观察组甘油三酯(TG)水平低于对照组(P<0.05),两组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平比较差异无统计学意义(P>0.05)。治疗24周后,观察组谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷氨酰转移酶(GGT)水平均低于对照组(P<0.05)。治疗24周后,观察组肝脾密度比高于对照组,肝脂肪含量低于对照组(P<0.05)。结论:达格列净辅助治疗T2DM合并MAFLD,可改善患者的胰岛素抵抗(IR),提高降低血糖的效果,并降低TG水平,从而降低肝脏脂肪含量,减轻肝功能损害。
Objective:To investigate the effect of Dapagliflozin in the adjuvant treatment of patients with type 2 diabetes mellitus(T2DM)and metabolic-dysfunction-associated fatty liver disease(MAFLD).Method:A total of 96 patients with T2DM and MAFLD admitted to Harbin First Hospital from June 2020 to October 2021 were selected as observation objects.According to the method of random number table,they were divided into control group and observation group,48 cases in each group.Both groups were given diet guidance.The control group was given routine hypoglycemic treatment,and the observation group was given Dapagliflozin Tablets on the basis of the control group.The blood glucose,islet function,blood lipid,liver function,liver fat content and liver spleen density ratio were compared between the two groups before and after 24 weeks of treatment.Result:After 24 weeks of treatment,glycosylated hemoglobin(HbA1c),fasting plasma glucose(FPG)and insulin resistance index(HOMA-IR)in the observation group were lower than those in the control group(P<0.05).After 24 weeks of treatment,the level of triglycerides(TG)in the observation group was lower than that in the control group(P<0.05),and there were no significant differences in the levels of total cholesterol(TC)and low-density lipoprotein cholesterin(LDL-C)between the two groups(P>0.05).After 24 weeks of treatment,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST)and glutamyltransferase(GGT)in the observation group were lower than those in the control group(P<0.05).After 24 weeks of treatment,the density ratio of liver and spleen in the observation group was higher than that in the control group,and the content of liver fat was lower than that in the control group(P<0.05).Conclusion:The adjuvant treatment of Dapagliflozin on T2DM and MAFLD can improve the insulin resistance(IR)of patients,improve the effect of lowering blood glucose,and reduce the level of TG,thus reducing the content of liver fat and reducing the damage of liver function.
作者
梁桂敏
邵宁
王莹
苏冬雪
柳杰
LIANG Guimin;SHAO Ning;WANG Ying;SU Dongxue;LIU Jie(Harbin First Hospital,Harbin 150010,China;不详)
出处
《中外医学研究》
2022年第36期139-142,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
